Prediction of gastric pH-mediated drug exposure using physiologically-based pharmacokinetic modeling: A case study of itraconazole.
Journal
CPT: pharmacometrics & systems pharmacology
ISSN: 2163-8306
Titre abrégé: CPT Pharmacometrics Syst Pharmacol
Pays: United States
ID NLM: 101580011
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
revised:
01
02
2023
received:
05
12
2022
accepted:
14
02
2023
medline:
19
6
2023
pubmed:
28
3
2023
entrez:
27
3
2023
Statut:
ppublish
Résumé
Abnormal gastric acidity, including achlorhydria, can act as a significant source of variability in orally administered drugs especially with pH-sensitive solubility profiles, such as weak bases, potentially resulting in an undesirable therapeutic response. This study aimed to evaluate the utility of physiologically-based pharmacokinetic (PBPK) modeling in the prediction of gastric pH-mediated drug exposure by using itraconazole, a weak base, as a case. An itraconazole PBPK model was developed on the mechanistic basis of its absorption kinetics in a middle-out manner from a stepwise in vitro-in vivo extrapolation to in vivo refinement. Afterward, an independent prospective clinical study evaluating gastric pH and itraconazole pharmacokinetics (PKs) under normal gastric acidity and esomeprazole-induced gastric hypoacidity was conducted for model validation. Validation was performed by comparing the predicted data with the clinical observations, and the valid model was subsequently applied to predict PK changes under achlorhydria. The developed itraconazole PBPK model showed reasonable reproducibility for gastric pH-mediated exposure observed in the clinical investigation. Based on the model-based simulations, itraconazole exposure was expected to be decreased up to 65% under achlorhydria, and furthermore, gastric pH-mediated exposure could be mechanistically interpreted according to sequential variation in total solubility, dissolution, and absorption. This study suggested the utility of PBPK modeling in the prediction of gastric pH-mediated exposure, especially for drugs whose absorption is susceptible to gastric pH. Our findings will serve as a leading model for further mechanistic assessment of exposure depending on gastric pH for various drugs, ultimately contributing to personalized pharmacotherapy.
Identifiants
pubmed: 36967484
doi: 10.1002/psp4.12959
pmc: PMC10272297
doi:
Substances chimiques
Itraconazole
304NUG5GF4
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
865-877Informations de copyright
© 2023 The Authors. CPT: Pharmacometrics & Systems Pharmacology published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.
Références
Expert Opin Drug Metab Toxicol. 2018 Sep;14(9):979-988
pubmed: 30028640
Aliment Pharmacol Ther. 2005 Jul 1;22(1):59-65
pubmed: 15963081
Mol Pharm. 2017 Dec 4;14(12):4321-4333
pubmed: 28817288
Mol Pharm. 2020 Jul 6;17(7):2329-2344
pubmed: 32427480
Eur J Clin Pharmacol. 1994;46(2):147-50
pubmed: 8039534
Helicobacter. 2016 Dec;21(6):586-595
pubmed: 27172105
Curr Opin Gastroenterol. 2016 Nov;32(6):452-460
pubmed: 27607343
Aliment Pharmacol Ther. 2015 Sep;42(6):719-30
pubmed: 26193978
Digestion. 2003;68(4):184-8
pubmed: 14691345
J Clin Pharm Ther. 2005 Jun;30(3):201-6
pubmed: 15896236
Mol Pharm. 2017 Dec 4;14(12):4305-4320
pubmed: 28771009
Antimicrob Agents Chemother. 1993 Apr;37(4):778-84
pubmed: 8388198
Aliment Pharmacol Ther. 1993 Jun;7(3):317-21
pubmed: 8117350
Expert Opin Drug Metab Toxicol. 2013 Jul;9(7):911-26
pubmed: 23641752
Eur J Pharm Biopharm. 2018 Aug;129:222-246
pubmed: 29879527
AAPS J. 2020 May 26;22(4):78
pubmed: 32458089
Expert Opin Pharmacother. 2000 Jan;1(2):287-304
pubmed: 11249550
BMC Health Serv Res. 2018 Jul 11;18(1):537
pubmed: 29996830
J Clin Pharmacol. 1997 Jun;37(6):535-40
pubmed: 9208361
Eur J Pharm Biopharm. 2017 Mar;112:234-248
pubmed: 27914234
Oncotarget. 2015 Jun 10;6(16):13858-98
pubmed: 26091351
Aliment Pharmacol Ther. 2009 Jun 15;29(12):1219-29
pubmed: 19302263
AAPS J. 2020 Oct 18;22(6):134
pubmed: 33070288
Physiol Rep. 2015 Jan 27;3(1):
pubmed: 25626870
Infect Drug Resist. 2018 Aug 22;11:1283-1297
pubmed: 30197526
AAPS J. 2016 Nov;18(6):1464-1474
pubmed: 27450228
Dig Dis Sci. 1996 Jul;41(7):1398-408
pubmed: 8689917
Expert Opin Drug Metab Toxicol. 2018 Apr;14(4):447-460
pubmed: 29620484
Eur J Clin Pharmacol. 1998 Apr;54(2):159-61
pubmed: 9626921
Clin Pharmacol Ther. 2018 Jul;104(1):88-110
pubmed: 29315504
Eur J Clin Pharmacol. 1989;36(4):423-6
pubmed: 2544431
CPT Pharmacometrics Syst Pharmacol. 2023 Jun;12(6):865-877
pubmed: 36967484
Acta Pharm Sin B. 2016 Sep;6(5):430-440
pubmed: 27909650
Gut. 1983 Apr;24(4):270-6
pubmed: 6832622
J Clin Pharmacol. 2020 Oct;60 Suppl 1:S160-S178
pubmed: 33205429
Mol Pharm. 2013 Nov 4;10(11):3970-9
pubmed: 23844623
Gut Liver. 2013 May;7(3):303-10
pubmed: 23710311
Proc Nutr Soc. 2013 Feb;72(1):173-7
pubmed: 23146206
Pharm Res. 1993 Feb;10(2):187-96
pubmed: 8456064